<ul><li>Many in the United States rely on fundraising platforms for life-saving treatments due to expensive biotech innovations like Zolgensma, a gene therapy for spinal muscular atrophy costing almost $2 million per patient.</li><li>Dr. Tejal Aslesh Tailor, a neuroscientist and molecular biologist, focuses on developing innovative therapeutic strategies for rare genetic disorders, aiming for accessibility and equal opportunity in healthcare.</li><li>Collaboration with key stakeholders, like Cure SMA, is emphasized by Dr. Tejal to bridge the gap between innovation and impact for patients, advocating for increased awareness and access to treatment.</li><li>Dr. Tejal stresses that innovation should be coupled with accessibility in healthcare, highlighting the importance of ensuring breakthrough treatments are available to all patients, regardless of economic status.</li></ul>

Dr. Tejal Aslesh Tailor: Biotech Innovation Without Access Isn’t Healthcare at All

Discover more